108 related articles for article (PubMed ID: 24485335)
1. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer.
Kanno Y; Watanabe M; Kimura T; Nonomura K; Tanaka S; Hatakeyama S
Acta Histochem; 2014 Jun; 116(5):708-12. PubMed ID: 24485335
[TBL] [Abstract][Full Text] [Related]
2. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.
Kosaka Y; Inoue H; Ohmachi T; Yokoe T; Matsumoto T; Mimori K; Tanaka F; Watanabe M; Mori M
Ann Surg Oncol; 2007 Sep; 14(9):2543-9. PubMed ID: 17597343
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
[TBL] [Abstract][Full Text] [Related]
4. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies.
Wu HH; Lapkus O; Corbin M
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):285-9. PubMed ID: 15536326
[TBL] [Abstract][Full Text] [Related]
6. The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins.
Daoud NA; Li G; Evans AJ; van der Kwast TH
J Clin Pathol; 2012 May; 65(5):437-40. PubMed ID: 22294716
[TBL] [Abstract][Full Text] [Related]
7. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
8. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry.
Helpap B; Köllermann J; Oehler U
J Pathol; 2001 Mar; 193(3):350-3. PubMed ID: 11241415
[TBL] [Abstract][Full Text] [Related]
9. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Stewart J; Fleshner N; Cole H; Sweet J
J Clin Pathol; 2007 Jul; 60(7):773-80. PubMed ID: 16916997
[TBL] [Abstract][Full Text] [Related]
10. [Predicative value of expression of TrkB and TRIM29 in biopsy tissues from preoperative gastroscopy in lymph node metastasis of gastric cancer].
Zhao MX; Ding SG; Liu LN; Wang Y; Zhang J; Zhang HJ; Zhang Y
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):376-9. PubMed ID: 22490895
[TBL] [Abstract][Full Text] [Related]
11. Over expression of ID-1 in prostate cancer.
Ouyang XS; Wang X; Lee DT; Tsao SW; Wong YC
J Urol; 2002 Jun; 167(6):2598-602. PubMed ID: 11992094
[TBL] [Abstract][Full Text] [Related]
12. TRIM29 regulates the p63-mediated pathway in cervical cancer cells.
Masuda Y; Takahashi H; Hatakeyama S
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2296-305. PubMed ID: 26071105
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
14. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer].
Yu T; Zhu SX; Zheng S; Chen SP
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784
[TBL] [Abstract][Full Text] [Related]
15. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
16. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
17. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
18. p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions.
Shiran MS; Tan GC; Sabariah AR; Rampal L; Phang KS
Med J Malaysia; 2007 Mar; 62(1):36-9. PubMed ID: 17682568
[TBL] [Abstract][Full Text] [Related]
19. Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer.
Ramnani DM; Bostwick DG
Mod Pathol; 1999 May; 12(5):443-4. PubMed ID: 10349979
[No Abstract] [Full Text] [Related]
20. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.
Shah IA; Schlageter MO; Stinnett P; Lechago J
Mod Pathol; 1991 Mar; 4(2):220-4. PubMed ID: 1710806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
